Articles tagged with Ovarian Cancer
A recent UCSF study analyzes the long-term effects of chemotherapy on women's reproductive health, finding that younger women are more likely to experience early menopause and infertility. The research provides new insights for patients and clinicians, enabling more strategic and personalized counseling about fertility preservation.
A phase 2 trial found that olaparib reduced tumor size in 41% of patients with ovarian cancer and no BRCA gene mutations. The treatment was generally well-tolerated and offered new hope for ovarian cancer treatment targeting DNA repair mechanisms.
Rush researchers identified a molecule, an antibody, in the bloodstream of infertile women that could be used to screen for high-risk individuals or those with early-stage ovarian cancer. Significant levels of mesothelin antibodies were found in women with premature ovarian failure and ovulatory dysfunction.
Researchers developed second-generation engineered T cells that successfully target and kill ovarian cancer cells in immune-deficient mice. The new technology overcomes limitations of first-generation approaches, showing improved persistence and survival signals for the engineered T cells.
A study found that many physicians do not follow guidelines for breast and ovarian cancer counseling and testing, affecting high-risk women who may miss out on life-saving interventions. Physicians were more likely to follow guidelines when accurately estimating patients' ovarian cancer risks.
Researchers at the University of Michigan Comprehensive Cancer Center have found that mesenchymal stem cells, normally used for wound healing, are recruited by cancer stem cells to fuel ovarian cancer growth. By blocking this process with a protein called BMP2, researchers may have discovered a potential therapy for ovarian cancer.
Researchers at The Pennsylvania State University College of Medicine discovered that low-dose naltrexone (LDN) has a potent antitumor effect on human ovarian cancer. Combining LDN with chemotherapy resulted in an additive inhibitory action on tumorigenesis, reducing DNA synthesis and cell replication.
Researchers from the Broad Institute and Harvard identified genes essential for ovarian tumor growth, including PAX8, which is altered in nearly one-fifth of surveyed tumors. The study's findings have implications for cancer research, suggesting that classification based on genetic mutations may be more revealing than tissue origin.
A multi-institutional study published in Nature reveals the genetic overview of ovarian cancer, showing mutations in one gene and frequent structural changes that contribute to its development. The findings could lead to better treatments for this aggressive form of cancer.
Using mice, researchers identified differences in viscoelastic properties between early and advanced stages of ovarian cancer. They found that benign cells are stiffer and more viscous than malignant cells, which is consistent with previous studies on other types of cancer.
Researchers from UNC Lineberger have contributed to a comprehensive view of cancer genes in ovarian cancer, identifying sets of genes associated with patient survival patterns and potential therapeutic targets.
The study analyzed over 300 tumor samples and found that 96% had mutated TP53 genes, while BRCA1 and BRCA2 were mutated in 30% of patients. The researchers identified a set of genes associated with worse or better patient outcomes, predicting survival rates.
The study provides a comprehensive view of cancer genes for any cancer type to date, identifying patterns in gene expression that predict patient survival. The results support four distinct subtypes of the disease based on genomic changes and highlight potential therapeutic targets using existing drugs.
Researchers have found that ovarian cancer cells use brute force to invade surrounding tissues and organs. The study identified key proteins involved in this process, providing a potential target for future treatments.
Researchers found that PET/CT imaging with the radiotracer 18F-FDG successfully detected 84% of benign and malignant tumors in patients with adnexal masses. This technology helps predict cancer stage and provide better treatment options for women diagnosed with ovarian cancer.
Researchers identified genetic mutations associated with lower cancer risk (e.g., MSH6) and increased risk (e.g., MLH1, MSH2) for ovarian and endometrial cancer in individuals with Lynch syndrome. The study provides age- and gene-specific risk estimates for each tumor type.
A clinical trial of 78,216 women found no reduction in ovarian cancer death risk with screening. Instead, screenings led to more invasive medical procedures and higher complication rates. The study suggests that annual screening may not be effective in detecting cancers early enough to reduce mortality.
New research finds that women with BRCA1/2 mutations who undergo prophylactic oophorectomy and take short-term HRT have a decreased risk of developing breast cancer. However, the procedure also increases the risk of early menopause and related quality-of-life issues.
Researchers developed a new test that identifies specific tumour types in ovarian cancer patients, enabling doctors to personalize treatment programmes. The test may improve survival rates by identifying aggressive forms of cancer that respond well to targeted drug treatments.
New studies released by ASCO highlight advances in cervical cancer screening, ovarian cancer detection, and prostate cancer risk prediction. The studies also explore genetic biomarkers for chemotherapy-induced neuropathy and potential treatments for relapsed ovarian cancer.
Researchers have found that over-expression of motor protein km23-1 can block human ovarian tumor growth, leading to eventual cancer cell death. This discovery offers promise for new therapies to treat ovarian cancer, a disease affecting U.S. women with an estimated 21,880 new cases and 13,850 deaths in 2010.
Researchers at Dana-Farber Cancer Institute have developed a laboratory model that mimics the process by which fallopian tube cells may morph into cancer cells. The model demonstrates that HGSOC begins in the fallopian tubes, providing powerful evidence for this theory.
An experimental drug called NVP-BEZ235 blocks a crucial cancer cell signaling pathway, slowing ovarian cancer growth and increasing survival in an ovarian cancer mouse model. The drug also re-sensitizes resistant cancer cells to platinum chemotherapy, offering new hope for fighting drug resistance.
Researchers at Oregon Health & Science University discovered a new approach to prevent ovarian cancer in high-risk women while maintaining fertility. The treatment involves removing the ovarian surface epithelium layer, which has no known function, without affecting ovary function or overall animal health.
A study published at the AACR Annual Meeting found that women with ovarian cancer and BRCA2 mutations had improved survival rates compared to those with BRCA1 mutations or no mutations. The five-year survival rate for women with BRCA2 mutations was 61%, significantly higher than those without mutations (36%). Further research is needed...
Researchers have developed nanoparticles loaded with siRNA to silence cancer-promoting genes in ovarian cancer, selectively shrinking or destroying tumors. The nanoparticles use high-density lipoprotein (HDL) as a delivery vehicle, which is taken up by cancer cells and not healthy tissue.
Philanthropists Foster and Lynn Friess are tripling-match donations up to $100,000 for TGen's unTEAL a cure event. The total raised will support groundbreaking research on ovarian cancer cases.
A new study published in Journal of Clinical Oncology found that adding targeted therapy bevacizumab to treatment for advanced ovarian cancer patients is not cost-effective. The researchers analyzed a clinical trial and found that the additional survival benefit was offset by high costs.
Researchers at York University have identified a key role for microRNA 376c in allowing ovarian cancer cells to thrive despite chemotherapy. By targeting the receptor ALK7, this microRNA enables cancer cells to survive and resist cell death.
Research using primary care records reveals that GPs often take more than a month to record an ovarian cancer diagnosis after receiving notification from specialists. In fact, one in ten cases took over four weeks, while 11% of records showed incorrect or premature diagnoses.
Scientists at Georgia Institute of Technology have found a regulatory RNA called miR-429 that can induce metastatic cancer cells to convert back into less invasive forms. This discovery may allow physicians to treat ovarian cancer more effectively with traditional chemotherapy.
African American women have lower incidence rates yet poorer survival rates for ovarian cancer compared to women of other races. The study aims to determine how risk factors differ between African American and white women, with the goal of preventing this deadly disease.
Researchers at Georgia Tech have developed a new treatment system that uses magnetic nanoparticles to capture free-floating cancer cells, slowing tumor progression in humans. The system aims to reduce chemotherapy side effects by removing the primary source of metastasis.
Preethi Gunaratne's research aims to unleash the body's natural cancer-fighting agents using microRNAs, which have been shown to suppress the growth of cancer cells. Gold nanoparticles are being explored as a potential carrier for these molecules, offering a promising treatment for ovarian cancer with minimal side effects.
Survival rates for breast, ovarian, colorectal, and lung cancer are higher in Australia, Canada, and Sweden compared to the UK and Denmark. International differences narrowed for breast cancer, but significant disparities remain in other cancers.
Researchers at the University of Gothenburg have confirmed that ovarian cancer tissue and healthy tissue smell different, using an electronic nose. The discovery has major practical implications for early detection and treatment of ovarian cancer.
Incorporating ovarian cancer subtypes into screening models reduces predicted mortality rates. However, catching slower-growing cancers won't significantly impact deaths compared to more lethal tumors.
Scientists have identified age-related gene-specific accumulation of DNA methylation that suppresses the critical TGF-beta pathway contributing to ovarian carcinogenesis. This finding provides crucial information for future translational research and may lead to targeted therapeutic interventions.
Researchers at Duke University Medical Center found evidence of epigenetics in ovarian cancer, specifically DNA methylation affecting the TGF-beta signaling pathway. This deregulation contributes to tumor growth and metastasis, highlighting a potential target for epigenetic therapies.
Researchers found that ovarian cancer screening can only slightly reduce mortality rates, highlighting the need for prevention and better treatments. For high-risk women, targeted screening may offer more hope in reducing deaths from ovarian cancer.
AnaLisa DiFeo will investigate microRNA profiles and their association with chemotherapy sensitivity in ovarian cancer tumors. Her research aims to identify new drug targets for overcoming chemoresistance and improving treatment outcomes.
A new study aims to discover the genetic and molecular underpinnings of small cell carcinoma of the ovary (SCCO), a rare and aggressive cancer affecting young women. Researchers will collect tumor and blood samples using advanced genomic approaches to understand the disease's origins and develop effective treatments.
In a Phase I trial, MK-4827 demonstrated anti-tumour responses in both sporadic and BRCA1/2 mutation-associated cancers. Patients with exhausted standard therapies showed significant shrinkage or stabilization of tumours for extended periods.
Using OncoMap, researchers can identify specific mutations in oncogenes that drive ovarian cancer growth and choose targeted drugs to halt tumor progression. The technique holds promise for personalized medicine in treating advanced ovarian cancer.
Researchers at the Centenary Institute discovered a new death pathway that can break drug resistance in ovarian cancer. The treatment, FTY720, kills ovarian cancer cells through necrosis, making it resistant to relapse. Further clinical trials are needed to confirm its effectiveness.
A study analyzing European Prospective Investigation into Cancer and Nutrition data found that current hormone therapy use increases the risk of ovarian cancer by 29%. The risk did not differ by type or duration of hormone therapy, suggesting a potential long-term hazard.
A study found that a peptide being tested to treat atherosclerosis significantly inhibited the growth of ovarian cancer in human cell lines and mouse models. The peptide, an apoA-I mimetic, was shown to be effective when administered via injection or ingestion, with minimal side effects.
Dr Clare Scott's VCA fellowship aims to uncover the origins of ovarian cancer and develop new laboratory models for studying human cancers. The funding will also support the use of a web portal, CART-WHEEL.org, to coordinate patient information and research studies.
The Program in Women's Oncology at Women & Infants Hospital will receive a $5,000 donation from Pink Heals Rhode Island to support the Patient Advocate Program. The program helps eliminate obstacles and stresses for women battling breast cancer by arranging transportation, financial assistance, and other services.
Women who inherit BRCA1 or BRCA2 gene mutations from their father are at increased risk of breast and ovarian cancer, yet this risk is often overlooked. A study found that patients with a paternal family history of cancer were 5 times more likely to be referred for genetic testing than those with a maternal family history.
A new study found that estrogen replacement therapy significantly speeds up ovarian cancer growth and increases the likelihood of cancer metastasizing to the lymph nodes. Researchers discovered estrogen-regulated genes specific to ER+ ovarian cancer that can be targeted with new anti-estrogen therapies.
A renowned gynecologic oncologist expresses concerns about a major ovarian cancer study, highlighting the need for targeted genetics-based treatments over delayed treatment timing. The study found no significant difference in survival rates between early and delayed chemotherapy groups.
A randomized study found that adding topotecan to carboplatin and paclitaxel did not improve progression-free survival in patients with ovarian cancer, but increased toxicity. The standard regimen of carboplatin and paclitaxel remains the best care for epithelial ovarian cancer.
A Phase II clinical trial of MLN8237, a selective Aurora A kinase inhibitor, demonstrates single-agent activity with durable disease control in some patients with ovarian cancer resistant to platinum-based chemotherapy. The study found encouraging responses in several patients, suggesting potential for future combination therapies.
A molecular imaging technique may help identify early response to treatment in cisplatin-resistant ovarian cancer, potentially reducing unnecessary side effects and offering more effective treatments. Researchers used a PET probe to monitor tumor growth in mice with human ovarian cancer.
A new randomised trial shows that starting chemotherapy earlier does not improve survival or quality of life for women with relapsed ovarian cancer. The study found that patients who received early treatment experienced a faster deterioration in quality of life, including role, emotional, social, and fatigue symptoms.
Research published in Annals of Oncology suggests that intrauterine devices releasing progestin hormone levonorgestrel combined with GnRH injections can halt and reverse cancer growth in women aged 40 or younger. The treatment has shown promise in treating specific types of endometrial cancer, preserving fertility for young women.
Two studies found new genetic variants linked to ovarian cancer risk in the general population, particularly in women with serous ovarian cancer. The variants were more common in women with aggressive disease and may be used for closer surveillance and preventive approaches.
A consortium of cancer researchers has identified four chromosome locations with genetic changes that may alter a woman's risk of developing ovarian cancer. These findings are based on a large genome-wide association study and could lead to individualized risk assessments for ovarian cancer.
Researchers have identified two genes, ARID1A and PPP2R1A, whose mutations are linked to ovarian clear cell carcinoma, a highly aggressive form of ovarian cancer. The study found that ARID1A mutations were present in over half of the tumors studied, suggesting a significant role in this type of cancer.